Eslicarbazepine acetate is an anticonvulsant agent used as an adjunct to treat partial-onset seizures in patients with inadequate clinical response to conventional antiepileptic therapy. Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy.
- Mechanism
- Curator reviewed
Eslicarbazepine acetate is converted to the active metabolite eslicarbazepine which carries out its anticonvulsant activity. The exact mechanism of action is unknown, but it is thought to involve the inhibition of voltage-gated sodium channels. In in vitro electrophysiological studies, eslicarbazepine was shown to inhibit repeated neuronal firing by stabilizing the inactivated state of voltage-gated sodium channels and preventing their return to the activated state. In vitro studies also showed eslicarbazepine inhibiting T-type calcium channels, which likely also has a role in anticonvulsant activity.
- Primary indication
- Eslicarbazepine acetate is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.Curator reviewed · 1 structured indication
- Formula / weight
- C17H16N2O3 · 296.326 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2014 · European Union, 2016
- Code names
- BIA 2-093 · SEP-0002093
- Brand names
Resolves to
QIALRBLEEWJACW-INIZCTEOSA-NSMILESCC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12What you can answer from here — as of September 23, 2026
Which drugs share a target with Eslicarbazepine acetate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account